Inj talimogene laherparepvec
Products billed under this code include Imlygic.
Payment limit per 1 million PFU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Imlygic.
Payment limit per 1 million PFU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Imlygic | Amgen Inc | 55513-0078-01 | 1 | $77.657 |
| Imlygic | Amgen Inc | 55513-0079-01 | 100 | $7,765.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $77.657 | +$0.318 | 1 million PFU | Inj talimogene laherparepvec | v1, posted September 17, 2026 |
| 3Q26 | $77.339 | +$3.397 | 1 million PFU | Inj talimogene laherparepvec | v1, posted September 15, 2026 |
| 2Q26 | $73.942 | +$0.003 | 1 million PFU | Inj talimogene laherparepvec | v1, posted September 15, 2026 |
| 1Q26 | $73.939 | +$0.004 | 1 million PFU | Inj talimogene laherparepvec | v1, posted September 15, 2026 |
| 4Q25 | $73.935 | +$0.388 | 1 million PFU | Inj talimogene laherparepvec | v1, posted September 8, 2026 |
| 3Q25 | $73.547 | +$3.171 | 1 million PFU | Inj talimogene laherparepvec | v1, posted March 10, 2026 |
| 2Q25 | $70.376 | +$0.009 | 1 million PFU | Inj talimogene laherparepvec | v1, posted March 10, 2026 |
| 1Q25 | $70.367 | +$0.006 | 1 million PFU | Inj talimogene laherparepvec | v1, posted December 19, 2025 |
| 4Q24 | $70.361 | +$0.402 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 11, 2025 |
| 3Q24 | $69.959 | +$3.157 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 11, 2025 |
| 2Q24 | $66.802 | +$0.215 | 1 million PFU | Inj talimogene laherparepvec | v1, posted March 11, 2025 |
| 1Q24 | $66.587 | +$0.292 | 1 million PFU | Inj talimogene laherparepvec | v1, posted December 19, 2024 |
| 4Q23 | $66.295 | +$0.241 | 1 million PFU | Inj talimogene laherparepvec | v1, posted October 10, 2024 |
| 3Q23 | $66.054 | +$3.697 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 5, 2024 |
| 2Q23 | $62.357 | −$0.321 | 1 million PFU | Inj talimogene laherparepvec | v1, posted February 23, 2024 |
| 1Q23 | $62.678 | +$2.058 | 1 million PFU | Inj talimogene laherparepvec | v1, posted December 6, 2023 |
| 4Q22 | $60.62 | +$0.942 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 22, 2023 |
| 3Q22 | $59.678 | +$2.504 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 9, 2023 |
| 2Q22 | $57.174 | −$0.043 | 1 million PFU | Inj talimogene laherparepvec | v1, posted December 14, 2022 |
| 1Q22 | $57.217 | −$0.044 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 8, 2022 |
| 4Q21 | $57.261 | +$0.747 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 2, 2022 |
| 3Q21 | $56.514 | +$2.421 | 1 million PFU | Inj talimogene laherparepvec | v1, posted June 2, 2022 |
| 2Q21 | $54.093 | +$0.076 | 1 million PFU | Inj talimogene laherparepvec | v1, posted March 1, 2022 |
| 1Q21 | $54.017 | – | 1 million PFU | Inj talimogene laherparepvec | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.